SCHEMBL14347751

SCHEMBL14347751

Cc1ccc(C(C)(C)CN2CCOCC2=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PER2 O15055 2/20 0.46
PTGS2 P35354 1/20 0.36
CYP2D6 P10635 1/20 0.35
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
CRY2 Q49AN0 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
CYP2C19 P33261 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
TP53 P04637 1/20 0.33
MAPK1 P28482 1/20 0.33
RAB9A P51151 1/20 0.33
FKBP1A P62942 1/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
RORC P51449 1/20 0.33
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 1/20 0.33
APAF1 O14727 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8350850 0.78 PER2 (0.46) PER2CYP2C19MEN1KMT2ATP53
SCHEMBL14347756 0.77 PER2 (0.47) PER2SMN1; SMN2CYP2C19MEN1KMT2A
SCHEMBL12228962 0.76 PER2 (0.48) PER2PRMT5WDR77CRY2SMN1; SMN2
SCHEMBL13299412 0.76 SMN1; SMN2 (0.49) PTGS2SMN1; SMN2MEN1KMT2ATP53
SCHEMBL12221 0.75 MEN1 (0.47) CYP2D6SMN1; SMN2CYP2C19MEN1KMT2A
SCHEMBL8350786 0.74 SMN1; SMN2 (0.38) SMN1; SMN2MEN1KMT2ATP53RAB9A
SCHEMBL15973077 0.73 PER2 (0.52) PER2PRMT5WDR77CRY2SMN1; SMN2
SCHEMBL5737672 0.72 POLB (0.47) PER2SMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL14347760 0.72 SMN1; SMN2 (0.51) CYP2D6SMN1; SMN2CYP2C19MEN1KMT2A
SCHEMBL24635088 0.71 KMT2A (0.49) CYP2D6CYP2C19MEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312214-B2 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-25 US disclosed